NeRRe Therapeutics are delighted to announce that Jo Craig, SVP for CMC at NeRRe Therapeutics, has been awarded an Eminent Fellowship of the Academy of Pharmaceutical Sciences (APS) UK for…
Read More
Mary Kerr CEO NeRRe Therapeutics and Managing Director KaNDY Therapeutics will be presenting a case study on the “Demerger of NT-814 to KaNDY Therapeutics, Business Model Innovation and Value Creation;…
Read More
Stevenage, UK, 21 June 2018 – KaNDy Therapeutics, a UK clinical-stage biotech company, today announces the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls for both KaNDy…
Read More
NeRRe Therapeutics CEO, Dr Mary Kerr, nominated to present at EBD Group’s BIO-Europe Spring 2018 conference, taking place March 12–14, 2018 in Amsterdam, Netherlands.
Read More
9th January 2018: NeRRe Therapeutics CEO, Dr Mary Kerr, presents at the Biotech Showcase, 11:30 AM Franciscan – B (Ballroom Level), Hilton San Francisco, San Francisco, CA 94102, USA
Read More
Say Hello to the Top 14 Female Entrepreneurs in European Biotech
Read More
Mary Kerr CEO NeRRe Therapeutics guest speaker at a recent Labiotech meeting in London
Read More
First-in-class once daily NT-814 spun out of NeRRe Therapeutics into new company Stevenage, UK, 27th September 2017 – KaNDy Therapeutics has been launched today to maximise the value of NT-814,…
Read More
Stevenage, UK, September 27th 2017 – NeRRe Therapeutics, which is developing a unique portfolio of neurokinin (NK)-1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity,…
Read More
